Respiratory syncytial virus, or RSV, is a common infection among both infants and older people that can lead to dangerous inflammation of the lungs and contributes to up to 240,000 hospitalizations in the U.S. annually. But until this year, there wasn’t a vaccine to protect against the virus. Now, there are several. In May, the FDA approved GSK’s Arexvy for adults over age 60, and followed with approval of Abrysvo from Pfizer for the same age group. In August, the agency approved the same Pfizer vaccine for pregnant women in order to protect newborns. And kids under age two whose moms weren’t vaccinated can now take advantage of Sanofi Pasteur’s Beyfortus, a one-time, injected antibody therapy that the FDA approved in July and improves on the previous treatment that required multiple shots throughout the winter season.
- Taylor Swift Is TIME's 2023 Person of the Year
- Meet the Nation Builders
- Why Cell Phone Reception Is Getting Worse
- Column: It's Time to Scrap the Abraham Accords
- Israeli Family Celebrates Release of Hostage Grandmother
- In a New Movie, Beyoncé Finds Freedom
- The Top 100 Photos of 2023
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time
